Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

By Boyce T.G.   Gruber W.C.   Coleman-Dockery S.D.   Sannella E.C.   Reed G.W.   Wolff M.   Wright P.F.  

Vaccine, Vol. 18, Iss. 1, 1999-08 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

By Halperin S.A.   Smith B.   Mabrouk T.   Germain M.   Trepanier P.   Hassell T.   Treanor J.   Gauthier R.   Mills E.L.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1240-1247

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

By Jackson L.A.   Austin G.   Chen R.T.   Stout R.   DeStefano F.   Gorse G.J.   Newman F.K.   Yu O.   Weniger B.G.   Vaccine Safety Datalink Study Group  

Vaccine, Vol. 19, Iss. 32, 2001-09 ,pp. : 4703-4709

Elsevier

Access to resources Recommend Favorite

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

By Nichol K.L.   Mallon K.P.   Mendelman P.M.  

Vaccine, Vol. 21, Iss. 17, 2003-05 ,pp. : 2216-2226

Elsevier

Access to resources Recommend Favorite

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

By Greenbaum E.   Furst A.   Kiderman A.   Stewart B.   Levy R.   Schlesinger M.   Morag A.   Zakay-Rones Z.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1232-1239

Elsevier

Access to resources Recommend Favorite